Metal Compounds in Cancer Therapy by S.p. FrickerMetal Compounds in Cancer Therapy by S.p. Fricker

Metal Compounds in Cancer Therapy

byS.p. Fricker

Paperback | October 29, 2012

Pricing and Purchase Info

$168.52 online 
$191.95 list price save 12%
Earn 843 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


The discovery of the antitumour activity of cisplatin in 1965 and its subsequent introduction into clinical trials in 1971 was the catalyst for a major international research effort investigating the potential of metal compounds in cancer therapy. Cisplatin now occupies an important place in the armamentarium of the oncologist due to its effectiveness in the treatment of testicular cancer. A second generation analogue, carbo­ platin, offers reduced toxicity together with therapeutic activity, which gives it a place in the front-line therapy of genitourinary cancers. These and other successes have encouraged the search for novel metal-based drugs for cancer therapy. Research has shown that metal compounds have potential for activity not only as cytotoxic antitumour agents, but also in areas such as adjuvant therapy, diagnosis and immunotherapy. The aim of this book is to review and describe the major achievements and developments arising from this international research effort. The contributing authors come from labora­ tories throughout Europe and America and represent the many disci­ plines characteristic of this research, such as clinical research, pharmacology, tumour biology and inorganic medicinal chemistry.
Title:Metal Compounds in Cancer TherapyFormat:PaperbackDimensions:256 pages, 23.5 × 15.5 × 0.01 inPublished:October 29, 2012Publisher:Springer-Verlag/Sci-Tech/TradeLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:9401045453

ISBN - 13:9789401045452

Look for similar items by category:


Table of Contents

List of contributors. Preface. Introduction. Platinum anticancer drugs. Gold. Ruthenium compounds in cancer therapy. Rhodium, iridium and palladium compounds as experimental anticancer drugs. Organometallic titanium, vanadium, niobium, molybdenum and rhenium complexes - early transition metal antitumour drugs. Antitumour activity of tin compounds. Gallium compounds in cancer therapy. Bleomycin and metal interactions. The in vivo use of metallic radioisotopes in cancer detection and imaging. Index.

Editorial Reviews

...provides a helpful entry and useful references to an advancing area mainly from the biochemical standpoint - Human & Experimental Toxicology; For those in the area it is an essential reading/reference work... It is an important series to launch at this time and is strongly recommended. - Platinum Metals Review